#competitiveintelligence is an active hashtag on Bluesky. In the last 30 days, 7 people shared 166 posts with it — around 6 a day. Activity is up 94% versus the previous week, peaking on Aug 27 with 14 posts.
Tags most often used together with #competitiveintelligence.
dlvr.it
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - manilatimes.net
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP) manilatimes.net
dlvr.it
RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy - Stocktwits
RARE Stock Jumps 13% — Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy Stocktwits
dlvr.it
Specialty Pharmacy Leaders to Convene for NASP inSPire2026 - The American Journal of Managed Care
Specialty Pharmacy Leaders to Convene for NASP inSPire2026 The American Journal of Managed Care
dlvr.it
REGENXBIO at Morgan Stanley conference: late-stage gene therapy push - Investing.com
REGENXBIO at Morgan Stanley conference: late-stage gene therapy push Investing.com
dlvr.it
Winners, weak spots, and warning signs for PD(L)1×VEGF bispecifics
This morning in Seoul at the WCLC meeting, one of the very last sessions grandly titled, “The Breakthrough Immunotherapy for…
dlvr.it
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? - The Motley Fool
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? The Motley Fool
dlvr.it
PTC Therapeutics completes ST-920 gene therapy acquisition - Investing.com
PTC Therapeutics completes ST-920 gene therapy acquisition Investing.com
dlvr.it
Ride Therapeutics raises $8M seed for non-viral gene delivery - Dealroom
Ride Therapeutics raises $8M seed for non-viral gene delivery Dealroom
dlvr.it
Beacon’s XLRP gene therapy meets pivotal U.S. endpoint - European Biotechnology Magazine
Beacon’s XLRP gene therapy meets pivotal U.S. endpoint European Biotechnology Magazine
dlvr.it
Beacon of hope for XLRP patients on Phase III gene therapy success - Clinical Trials Arena
Beacon of hope for XLRP patients on Phase III gene therapy success Clinical Trials Arena
dlvr.it
PTC Therapeutics completes ST-920 gene therapy acquisition - Investing.com
PTC Therapeutics completes ST-920 gene therapy acquisition Investing.com
dlvr.it
Ride Therapeutics raises $8M seed for non-viral gene delivery - Dealroom
Ride Therapeutics raises $8M seed for non-viral gene delivery Dealroom
dlvr.it
Beacon’s XLRP gene therapy meets pivotal U.S. endpoint - European Biotechnology Magazine
Beacon’s XLRP gene therapy meets pivotal U.S. endpoint European Biotechnology Magazine
dlvr.it
Beacon of hope for XLRP patients on Phase III gene therapy success - Clinical Trials Arena
Beacon of hope for XLRP patients on Phase III gene therapy success Clinical Trials Arena
dlvr.it
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
dlvr.it
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - manilatimes.net
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP) manilatimes.net
dlvr.it
Scientists engineer a miniature CRISPR protein to silence genes and curb hepatitis B - Bioengineer.org
Scientists engineer a miniature CRISPR protein to silence genes and curb hepatitis B Bioengineer.org
dlvr.it
Bitrobius targets mitochondrial gene delivery with £700k ARIA grant - Laboratory News
Bitrobius targets mitochondrial gene delivery with £700k ARIA grant Laboratory News
dlvr.it
Ocugen Lays Out Three-Year FDA Roadmap as Gene Therapy Timelines Stretch to 2028 - AD HOC NEWS
Ocugen Lays Out Three-Year FDA Roadmap as Gene Therapy Timelines Stretch to 2028 AD HOC NEWS
dlvr.it
Wisconsin sisters with rare hearing loss receive newly approved therapy - Roanoke Times
Wisconsin sisters with rare hearing loss receive newly approved therapy Roanoke Times
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.